Clover Health Investor Day Presentation Deck

Step 2 Example: How The Clover Assistant Surfaces Evidence-Based Protocols At The Point Of Care 1 2 Provides clinical recommendations help doctors develop evidence-based treatment plans Shares with the physicians the specific reasons why a recommendation is being made Identifies clinical guidelines on treatment protocols 3 applicable to a member's specific conditions and disease burden Identifies potential costs or blockers that could 4 prevent a patient adhering to the proposed clinical recommendations Physicians provide specific information or feedback to 5 Clover on how or why they are treating their patient, our member 1 Type 2 Diabetes: Injectable Therapy for Elevated A1C 5 Clover's latest HbA1C result is 2 10% for this patient. Consider starting or restarting one of the following injectable therapies (*GLP-1 agonists are generally preferred; if starting insulin, long-acting is recommended): Dulaglutide (TRULICITY)* $$$ 98 98 98 98 Glargine (BASAGLAR) $$$ Detemir (LEVEMIR) $$$ Degludec (TRESIBA) $$$ NOVOLIN N $$$ Degludec/Liraglutide (XULTOPHY 100/3.6)* $$$ Medication prescribed 08 Did not prescribe medication 98 Save task 96 98 Semaglutide (OZEMPIC)* $$$ Exenatide (BYDUREON)* $$$ 4 $= lowest patient cost, $$$$$ - highest patient cost, comparative drug costs for patient shown from Clover formulary. Actual cost may change during the year. Liraglutide (VICTOZA)* $$$ Glargine/Lixisenatide (SOLIQUA Please ensure that your patient: - Does not have drug allergies or potential drug-drug interactions. Please use your clinical judgment. 100/33)* $$$ 2 Why we recommend this RELEVANT PATIENT HISTORY A Diagnosis Type 2 diabetes mellitus without complications 07/31/2019 ✓ Medications > REQUIRED ✓ Lab results Expand all CLINICAL GUIDELINES 3 The ADA recommends initiating injectable therapy when a patient's A1C is ≥ 10% to more expeditiously achieve glycemic control. 2019 ADA Standards of Care in Diabetes 10

View entire presentation